Jamie Hartford 1

July 29, 2016

1 Min Read
CVRx Inc.

CVRx says its implantable Barostim System "triggers the body's own natural blood flow regulation system" to treat high blood pressure and heart failure. The device has the CE Mark and may be sold in Europe but is limited to investigational use in the United States, although it has received Expedited Access Pathway from FDA. The Minneapolis-based company attracted $46.5 million in venture funding this past quarter.

Continue >>

[image courtesy of the company]

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like